HANGZHOU TIGERMED CONSULTING CO., LTD.
杭州泰格醫藥科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 3347)

INSIDE INFORMATION
UPDATE ON INVESTIGATION AGAINST DIRECTORS AND CONTROLLING SHAREHOLDERS

This announcement is made by Hangzhou Tigermed Consulting Co., Ltd. (the "**Company**", together with its subsidiaries, collectively the "**Group**") pursuant to Rules 13.09(2), 13.51(2) and 13.51B(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated May 12, 2026 and May 13, 2026 in relation to a case filing notice received by Mr. Ye Xiaoping ("**Mr. Ye**"), and Ms. Cao Xiaochun ("**Ms. Cao**"), directors and controlling shareholders of the Company, from the China Securities Regulatory Commission ("**CSRC**") in relation to suspected violations of laws and regulations regarding information disclosure related to changes in the Company's shareholding in A shares.

The Company is notified that on September 11, 2026, Mr. Ye and Ms. Cao received the Decision on Imposing the Measure of Issuing a Warning Letter to Ye Xiaoping and Cao Xiaochun (《關於對葉小平、曹曉春採取出具警示函措施的決定》) (the "**Warning Letter**") and the Advance Notice of Administrative Penalty (Zhe Penalty Zi [2026] No. 21 (《行政處罰事先告知書》(浙處罰字[2026] 21號)) (the "**Notice**") from the Zhejiang Regulatory Bureau of the CSRC (the "**Zhejiang Regulatory Bureau**").

The main contents of the Warning Letter are as follows:

On December 7, 2022, Mr. Ye and Ms. Cao voluntarily reduced their respective shareholdings in A shares of the Company, resulting in an aggregate decrease of 1% in equity interest. Mr. Ye and Ms. Cao then failed to timely disclose such equity interest changes and only disclosed the relevant information on May 12, 2026. The aforesaid acts are in violation with paragraph 3 of article 13 of the Measures for the Administration of Takeovers of Listed Companies (CSRC Order No. 166) (《上市公司收購管理辦法》(證監會令第166號)) and paragraph 3 of article 13 of the Measures for the Administration of Takeovers of Listed Companies (CSRC Order No. 227) (《上市公司收購管理辦法》(證監會令第227號)).

Pursuant to article 75 of the Measures for the Administration of Takeovers of Listed Companies (CSRC Order No. 227) (《上市公司收購管理辦法》(證監會令第227號)), the Zhejiang Regulatory Bureau has issued the Warning Letter to Mr. Ye and Ms. Cao, which will be recorded in the securities and futures market integrity records. Mr. Ye and Ms. Cao shall earnestly learn lessons, strengthen the study of securities laws and regulations, strictly standardize trading and disclosure activities, prevent recurrence of such violations, and submit a written report to the Zhejiang Regulatory Bureau within 10 working days upon receipt of the Warning Letter.

Mr. Ye and Ms. Cao may apply for administrative reconsideration to the CSRC within 60 days upon receipt of this Decision, or institute an action before a people's court with competent jurisdiction within six months upon receipt of the Warning Letter.

The main contents of the Notice are as follows:

On September 20, 2019, the aggregate proportion of voting shares issued by the Company held by Mr. Ye and Ms. Cao reached a cumulative change of 5%. Mr. Ye and Ms. Cao failed to timely disclose the Simplified Report on Changes in Equity Interests (《簡式權益變動報告書》) and only made supplementary disclosures on May 12, 2026.

The Zhejiang Regulatory Bureau is of the opinion that the aforesaid acts of Mr. Ye and Ms. Cao were in violation of paragraph 2 of article 86 of the Securities Law of the People's Republic of China (as amended in 2005) (the "**2005 Securities Law**") and paragraph 2 of article 63 of the Securities Law of the People's Republic of China (as amended in 2019) (the "**Securities Law**"), and constitute information disclosure violations as specified in paragraph 2 of article 193 of the 2005 Securities Law and paragraph 1 of article 197 of the Securities Law.

Based on the facts, nature, circumstances and degree of social harm of the parties' illegal acts, and pursuant to paragraph 1 of article 197 of the Securities Law, the Zhejiang Regulatory Bureau proposes to impose a warning and a fine of RMB500,000 to each of Mr. Ye and Ms. Cao.

In accordance with articles 45, 63 and 64 of the Administrative Penalty Law of the People's Republic of China and the relevant provisions of the Rules of the China Securities Regulatory Commission on Administrative Penalty Hearings (《中國證券監督管理委員會行政處罰聽證規則》), Mr. Ye and Ms. Cao shall have the right to state and defend their cases and request a hearing in response to the administrative penalty proposed by the Zhejiang Regulatory Bureau.

For further details in respect of the Warning Letter and the Notice, please refer to the overseas regulatory announcement of the Company dated September 11, 2026.

The board of directors of the Company are of the view that the Warning Letter and the Notice relate to information disclosure matters arising from historical changes in shareholdings in A shares of the Company, and such shareholding changes have already been disclosed subsequently in the Company's announcements and periodic reports. Such matters are unrelated to the Company's operations and will not affect the Group's normal operations. Further announcement(s) will be made to keep the shareholders of the Company and the public informed of the development in this matter in due course.

The shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, September 11, 2026

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee Director is Mr. Wu Hao; the independent non-executive Directors are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu Paul Yu Hay.